| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/200 - 1/1000 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | P21; CIP1; SDI1; WAF1; CAP20; CDKN1; MDA-6; p21CIP1 |
| Entrez GeneID | 1026 |
| clone | 2B7F8 |
| WB Predicted band size | 18.1kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human CDKN1A (AA: 1-164) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于CDKN1A(p21)抗体的3篇代表性文献，涵盖其应用及功能研究：
---
1. **文献名称**：*WAF1. a potential mediator of p53 tumor suppression*
**作者**：El-Deiry, W.S. et al.
**摘要**：该研究首次克隆并鉴定了CDKN1A(p21/WAF1)，发现其受p53调控并在细胞周期停滞中起关键作用。文中使用特异性抗体通过Western blot验证p21在DNA损伤后的表达上调，证实其作为p53下游效应分子的功能。
2. **文献名称**：*The role of p21 in apoptosis, senescence, and cancer therapy*
**作者**：Gartel, A.L. & Tyner, A.L.
**摘要**：综述了p21在细胞凋亡、衰老及癌症中的双重作用。总结了多篇研究中使用CDKN1A抗体的实验方法(如免疫组化、流式细胞术)，揭示了p21在肿瘤组织中的表达差异及其预后意义。
3. **文献名称**：*p21 in cancer: intricate networks and multiple activities*
**作者**：Abbas, T. & Dutta, A.
**摘要**：探讨p21在癌症中的复杂调控网络，包括其依赖/非依赖细胞周期的功能。通过免疫沉淀和Western blot实验(使用多种CDKN1A抗体)，揭示了p21与CDK及PCNA的相互作用机制。
---
**备注**：上述文献中抗体的应用主要集中在验证蛋白表达、定位及相互作用，为研究p21的生物学功能提供了技术支撑。如需具体实验方案或抗体品牌信息，建议进一步筛选方法学论文。
The CDKN1A antibody is a crucial tool in molecular and cellular biology research, targeting the CDKN1A gene product, p21 (also known as p21WAF1/Cip1). This protein is a cyclin-dependent kinase inhibitor that regulates cell cycle progression by binding to and inhibiting cyclin-CDK complexes, thereby blocking G1/S phase transition. p21 plays a central role in cellular responses to DNA damage, senescence, and apoptosis, acting as a downstream effector of tumor suppressor p53. Dysregulation of p21 is implicated in cancer, aging, and neurodegenerative diseases, making it a key focus in disease mechanism studies.
CDKN1A antibodies are widely used in techniques like Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), and flow cytometry to detect p21 expression levels and localization. These applications help researchers investigate cell cycle control, DNA damage responses, and therapeutic targets. Antibodies may be monoclonal or polyclonal, with monoclonal variants offering higher specificity and batch consistency. Validation often includes knockout cell line controls or peptide blocking experiments to confirm target specificity.
Commercially available CDKN1A antibodies are offered by major suppliers (e.g., Cell Signaling Technology, Abcam), with species reactivity typically covering human, mouse, and rat samples. Proper antibody selection depends on experimental needs, including compatibility with specific assay formats and post-translational modification detection requirements. Recent studies also explore p21's potential as a biomarker, further driving antibody development for diagnostic applications.
×
